サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794489

乗り物酔い薬の世界市場

Motion Sickness Drugs

出版日
ページ情報
英文 270 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.52円
乗り物酔い薬の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 270 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

乗り物酔い薬の世界市場は2030年までに7億2,140万米ドルに達する見込み

2024年に5億9,200万米ドルと推定される乗り物酔い薬の世界市場は、分析期間2024-2030年にCAGR 3.3%で成長し、2030年には7億2,140万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗ヒスタミン薬は、CAGR 4.1%を記録し、分析期間終了時には4億9,010万米ドルに達すると予測されます。抗コリン薬セグメントの成長率は、分析期間中CAGR 2.0%と推定されます。

米国市場は1億6,130万米ドルと推定、中国はCAGR6.4％で成長予測

米国の乗り物酔い薬市場は、2024年に1億6,130万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億4,430万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.6％と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の乗り物酔い薬市場- 主要動向と促進要因のまとめ

なぜ乗り物酔い薬は旅行や医療現場で広く使われているのか？

乗り物酔い薬は、旅行中やシミュレーション中の移動によって引き起こされるめまい、吐き気、嘔吐、冷や汗などの症状を予防・管理するために使用されます。これらの薬剤は、中枢神経系に作用して内耳からの信号を遮断したり、平衡感覚に関連する経路の過剰な刺激を抑えたりすることで効果を発揮します。これらの薬剤は、空路、海路、陸路の移動のほか、術後のケアや前庭障害にも一般的に使用されています。乗り物酔いは、反復的または予期せぬ動きを伴う活動中に最も頻繁に経験されるため、動きに対する感受性が高い人には薬理学的介入が重要となります。

乗り物酔い治療薬は、市販薬と処方薬の両方があり、経口錠剤、経皮吸収パッチ、チュアブル錠、液剤などがあります。広く使用されている薬剤クラス別には、メクリジンやジメンヒドリナートなどの抗ヒスタミン薬、スコポラミンなどの抗コリン薬、プロメタジンなどのドパミン拮抗薬などがあります。治療法の選択は、旅行期間、症状の重症度、使用者の耐性によって異なります。これらの薬剤は、治療効果だけでなく予防効果もあるため、日常的な使用にも一時的な管理にも適しています。

利便性と忍容性を向上させるために、製剤はどのように進化しているか？

メーカー各社は、より長い緩和効果、使いやすさ、副作用の少なさを提供するドラッグデリバリーシステムにますます力を注いでいます。数日間にわたって持続的に放出される経皮パッチは、長時間の船旅や飛行機での移動に好まれています。チュアブル錠や口腔内崩壊錠は、小児や嚥下困難な患者への投与に便利です。鎮静作用の少ない製剤は、特に旅行中に注意力を維持したい旅行者に人気を集めています。

新しい製品は、第一世代の抗ヒスタミン薬や抗コリン薬によくみられる口渇、眠気、目のかすみなどの副作用を最小限に抑えることを目的としています。前庭症状と胃腸症状の両方に対応する併用療法も開発中です。さらに、バーチャルリアリティ（VR）体験のような動きに基づくエンターテインメント・プラットフォームの成長により、動きに起因する不快感を軽減しながら感覚の明瞭さを維持する非鎮静性速効性製剤に対する新たな需要領域が開拓されています。

地域別に市場需要を形成しているエンドユーザー動向は？

乗り物酔い薬の使用は、頻繁に旅行する人、クルーズの乗客、航空関係者の間で特に多いです。海外旅行の再開に伴い、空港、薬局、旅行クリニックでこれらの医薬品に対する需要が回復しています。乗り物酔いしやすい小児や老年人口は、よりマイルドで忍容性の高い製剤を求める重要な消費者層を形成しています。ヘルスケアでは、乗り物酔い薬は前庭偏頭痛や内耳障害の治療補助薬としても使われています。

レジャーボート、アウトドア観光、乗り物系遊園地などでも、乗り物酔い治療薬が一般的に推奨されています。軍事・防衛用途では、飛行乗務員や海軍要員における運動誘発性の吐き気の管理はミッション・クリティカルであると考えられており、長時間作用型でパフォーマンスを維持する選択肢の使用が促されています。このようなエンドユーザーの多様な環境は、製剤開発、用法嗜好、流通戦略に世界的に影響を与え続けています。

乗り物酔い治療薬の消費と技術革新の成長の原動力は？

乗り物酔い薬市場の成長は、世界の旅行の増加、消費者の意識の向上、製品デザインの進化に関連するいくつかの要因によってもたらされます。クルーズや冒険旅行産業の拡大により、動きの激しい環境における予防薬の需要が高まっています。前庭障害の診断件数の増加と治療へのアクセスの向上が、処方薬の普及に寄与しています。経皮吸収型製剤や使いやすい経口製剤の革新により、さまざまな層がこれらの製品を利用しやすくなっています。乗り物酔い薬は、電子薬局や調剤薬局など複数の小売チャネルで入手できるため、製品の認知度と利便性が向上しています。さらに、フライトシミュレーターやVRアプリケーションのような動きの多いデジタル環境に触れる機会が増えたことで、鎮静作用がなく即効性のある乗り物酔い薬の新たな使用事例が生まれ、先進国市場と新興国市場の着実な成長を支えています。

セグメント

薬剤クラス別（抗ヒスタミン薬、抗コリン薬）;流通チャネル別（オフライン流通チャネル、オンライン流通チャネル）

調査対象企業の例

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bayer AG
  • BONINE（WellSpring Pharmaceutical）
  • Cipla Limited
  • CVS Health Corporation
  • GlaxoSmithKline plc（GSK）
  • Lupin Limited
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.
  • Reliefband Technologies LLC
  • Sanofi S.A.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd
  • WellSpring Pharmaceutical Corp.
  • Zydus Lifesciences Ltd.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37438

Global Motion Sickness Drugs Market to Reach US$721.4 Million by 2030

The global market for Motion Sickness Drugs estimated at US$592.0 Million in the year 2024, is expected to reach US$721.4 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Antihistamines, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$490.1 Million by the end of the analysis period. Growth in the Anticholinergics segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$161.3 Million While China is Forecast to Grow at 6.4% CAGR

The Motion Sickness Drugs market in the U.S. is estimated at US$161.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$144.3 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Motion Sickness Drugs Market - Key Trends & Drivers Summarized

Why Are Motion Sickness Drugs Widely Used in Travel and Medical Settings?

Motion sickness drugs are used to prevent and manage symptoms such as dizziness, nausea, vomiting, and cold sweats caused by movement during travel or simulation. These drugs work by acting on the central nervous system to block signals from the inner ear or reduce overstimulation of the balance-related pathways. They are commonly used for air, sea, and land travel as well as in post-operative care and vestibular disorders. Motion sickness is most frequently experienced during activities involving repetitive or unanticipated motion, making pharmacological intervention important for individuals with high sensitivity to movement.

These drugs are available in both over-the-counter and prescription forms, in oral tablets, transdermal patches, chewable tablets, and liquid formulations. Widely used drug classes include antihistamines such as meclizine and dimenhydrinate, anticholinergics such as scopolamine, and dopamine antagonists like promethazine. The choice of therapy depends on duration of travel, severity of symptoms, and user tolerance. These medications provide preventive as well as therapeutic relief, making them suitable for routine use and episodic management alike.

How Are Drug Formulations Evolving to Improve Convenience and Tolerability?

Manufacturers are increasingly focusing on drug delivery systems that offer extended relief, ease of use, and fewer side effects. Transdermal patches, which provide continuous release over several days, are preferred for long-duration sea or air travel. Chewable and orally disintegrating tablets offer convenient administration for children or patients with swallowing difficulties. Formulations with reduced sedative effects are gaining popularity, especially for travelers who wish to remain alert during trips.

Newer products aim to minimize dry mouth, drowsiness, and blurred vision-side effects commonly associated with first-generation antihistamines and anticholinergics. Combination therapies that address both vestibular and gastrointestinal symptoms are also under development. Additionally, the growth of motion-based entertainment platforms such as virtual reality (VR) experiences has opened a new area of demand for non-sedating, rapid-acting formulations that maintain sensory clarity while reducing motion-induced discomfort.

What End-User Trends Are Shaping Market Demand Across Regions?

Use of motion sickness drugs is particularly high among frequent travelers, cruise passengers, and aviation personnel. With the resumption of international travel, demand for these medications is rebounding across airports, pharmacies, and travel clinics. Pediatric and geriatric populations, who are often more susceptible to motion sickness, form a significant consumer base for milder, well-tolerated formulations. In healthcare settings, motion sickness medications are also used as adjuncts in treating vestibular migraines and inner ear disorders.

The leisure boating sector, outdoor adventure tourism, and ride-based amusement parks represent additional market niches where such drugs are commonly recommended. In military and defense applications, managing motion-induced nausea in flight crews and naval personnel is considered mission-critical, prompting the use of long-acting and performance-preserving options. These diverse end-user settings continue to influence formulation development, dosage preferences, and distribution strategies globally.

What Is Driving Growth in Motion Sickness Drug Consumption and Innovation?

Growth in the motion sickness drugs market is driven by several factors related to increased global travel, higher consumer awareness, and evolving product design. Expansion of the cruise and adventure tourism industry is raising demand for preventive medications in high-motion environments. Rising diagnosis of vestibular disorders and better access to treatment are contributing to prescription drug uptake. Innovation in transdermal delivery systems and user-friendly oral formats is making these products more accessible to varied demographics. The availability of motion sickness drugs through multiple retail channels, including e-pharmacies and in-transit dispensaries, is enhancing product visibility and convenience. Additionally, increased exposure to motion-heavy digital environments such as flight simulators and VR applications is creating new use cases for non-sedating, fast-acting motion sickness drugs, supporting steady growth across developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Motion Sickness Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antihistamines, Anticholinergics); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bayer AG
  • BONINE (WellSpring Pharmaceutical)
  • Cipla Limited
  • CVS Health Corporation
  • GlaxoSmithKline plc (GSK)
  • Lupin Limited
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.
  • Reliefband Technologies LLC
  • Sanofi S.A.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd
  • WellSpring Pharmaceutical Corp.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Motion Sickness Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Air, Sea, and Road Travel Increases Use of Preventive Pharmaceuticals for Motion Disorders
    • Expansion of Global Tourism and Business Travel Sustains Long-Term Demand for OTC and Prescription Options
    • Growing Consumer Awareness of Early Symptoms Encourages Proactive Use of Anti-Nausea Treatments
    • Availability of Multiple Dosage Forms Enhances User Convenience and Compliance
    • Increasing Prevalence of Motion Sickness Among Children and Elderly Supports Market Expansion
    • Advancements in Non-Drowsy and Extended-Release Formulations Drive Product Differentiation
    • Rising Demand for Natural and Herbal Remedies Opens New Avenues for Plant-Based Alternatives
    • Growth in E-Commerce and Online Pharmacies Boosts Global Access to Motion Sickness Drugs
    • Expansion of Aviation and Cruise Industries Generates Bulk Demand for In-Transit Medical Stock
    • Inclusion in Travel Health Kits and Retail Travel Accessories Increases Point-of-Sale Presence
    • Rising Need for Motion Sickness Solutions in Virtual Reality (VR) Applications Creates Emerging Use Cases
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Motion Sickness Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Motion Sickness Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Motion Sickness Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Motion Sickness Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Motion Sickness Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Motion Sickness Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION